1. Relationship between HER2 and JAK/STAT-SOCS3 signaling pathway and clinicopathological features and prognosis of ovarian cancer. Issue 5 (4th May 2017) Authors: Shang, An-Quan; Wu, Jian; Bi, Feng; Zhang, Yu-Jie; Xu, Lei-Rong; Li, Ling-Ling; Chen, Fei-Fei; Wang, Wei-Wei; Zhu, Jian-Jun; Liu, You-Yi Journal: Cancer biology & therapy Issue: Volume 18:Issue 5(2017) Page Start: 314 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Tumor calcification as a prognostic factor in cetuximab plus chemotherapy-treated patients with metastatic colorectal cancer. Issue 2 (February 2019) Authors: Zhou, Yuwen; Zhang, Jing; Dan Pu, ; Bi, Feng; Chen, Ye; Liu, Jiyan; Li, Qiu; Gou, Hongfeng; Wu, Bing; Qiu, Meng Journal: Anti-cancer drugs Issue: Volume 30:Issue 2(2019) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Patient‐based cost‐effectiveness analysis of FOLFIRI versus FOLFOX7 for advanced gastric adenocarcinoma in China: A 4‐year prospective randomised phase II study. (11th December 2019) Authors: Wen, Feng; Zheng, Hanrui; Zhang, Pengfei; Zhou, Jing; Chen, Hongdou; Zhou, Kexun; Li, Qiu; Bi, Feng Journal: European journal of cancer care Issue: Volume 29:Number 1(2020) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Expert consensus on maintenance treatment for metastatic colorectal cancer in China. Issue 1 (14th January 2016) Authors: Xu, Rui‐Hua; Shen, Lin; Li, Jin; Xu, Jian‐Ming; Bi, Feng; Ba, Yi; Bai, Li; Shu, Yong‐Qian; Liu, Tian‐Shu; Li, Yu‐Hong; Bai, Chun‐Mei; Yuan, Xiang‐Lin; Zhang, Jun; Chen, Gong; Zhou, Ai‐Ping; Yuan, Ying; Wang, Xi‐Jing; Qian, Xiao‐Ping; Deng, Yan‐Hong Journal: Cancer communications Issue: Volume 35:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. CMAB009 plus irinotecan versus irinotecan‐only as second‐line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‐type metastatic colorectal cancer patients: promising findings from a prospective, open‐label, randomized, phase III trial. Issue 1 (24th May 2019) Authors: Shi, Yuankai; Li, Jin; Xu, Jianming; Sun, Yan; Wang, Liwei; Cheng, Ying; Liu, Wei; Sun, Guoping; Chen, Yigui; Bai, Li; Zhang, Yiping; He, Xiaohui; Luo, Yi; Wang, Zhehai; Liu, Yunpeng; Yao, Qiang; Li, Yuhong; Qin, Shukui; Hu, Xiaohua; Bi, Feng Journal: Cancer communications Issue: Volume 39:Issue 1(2019) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Specific surface area and electron donating capacity determine biochar's role in methane production during anaerobic digestion. (May 2020) Authors: Qin, Yong; Yin, Xiaosi; Xu, Xingkun; Yan, Xiangrui; Bi, Feng; Wu, Weixiang Journal: Bioresource technology Issue: Volume 303(2020) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Regorafenib in Chinese patients with metastatic colorectal cancer: Subgroup analysis of the phase 3 CONCUR trial. Issue 8 (28th January 2020) Authors: Xu, Jianming; Xu, Rui‐Hua; Qin, Shukui; Pan, Hongming; Bai, Yuxian; Chi, Yihebali; Wang, Liwei; Bi, Feng; Cheng, Ying; Liu, Tianshu; Ma, Dong; Shen, Lin; Ba, Yi; Liang, Jun; Wang, Xin; Yau, Thomas C C; Ma, Brigette B; Yeh, Kun‐Huei; Lin, Jen‐Kou; Kappeler, Christian Journal: Journal of gastroenterology and hepatology Issue: Volume 35:Issue 8(2020) Page Start: 1307 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. 78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. (9th November 2020) Authors: Ye, Dingwei; Zhou, Aiping; Zou, Qing; Li, Hanzhong; Fu, Cheng; Hu, Hailong; Huang, Jian; Shen, Wei; Zhang, Yun; Ma, Xiaopeng; Zhang, Pei; Huang, Ruiqi; Qiu, Xiusong; Zhang, Lilin; Bi, Feng Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. 78 T-Cell, MHC i, and tumor intrinsic gene signatures predict clinical benefit and resistance to tislelizumab monotherapy in pretreated PD-L1+ urothelial carcinoma. (10th December 2020) Authors: Ye, Dingwei; Zhou, Aiping; Zou, Qing; Li, Hanzhong; Fu, Cheng; Hu, Hailong; Huang, Jian; Shen, Wei; Zhang, Yun; Ma, Xiaopeng; Zhang, Pei; Huang, Ruiqi; Qiu, Xiusong; Zhang, Lilin; Bi, Feng Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A48 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Ferroptosis in the tumor microenvironment: perspectives for immunotherapy. Issue 9 (September 2021) Authors: Xu, Huanji; Ye, Di; Ren, Meiling; Zhang, Hongying; Bi, Feng Journal: Trends in molecular medicine Issue: Volume 27:Issue 9(2021) Page Start: 856 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗